Novel heterocyclic indazole derivatives of formula (I),(see formula I)wherein L, Q, R, X, Y, R3, R4 and R5 are defined in the specification, are SGKinhibitors and can be used for treating SGK-related diseases and disorderssuch asdiabetes, obesity, metabolic syndrome (dyslipidemia), systemic and pulmonaryhypertension, cardiovascular diseases and renal diseases, in general for anytype offibroses and inflammatory processes.
